What's in Universidade Federal de Pernambuco's pipeline?

Universidade Federal de Pernambuco has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Universidade Federal de Pernambuco's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universidade-federal-de-pernambuco.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Universidade Federal de Pernambuco — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universidade Federal de Pernambuco pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
Cefazolin used in antimicrobial prophylaxis	Cefazolin used in antimicrobial prophylaxis	marketed
small amount of undiluted C3F8	small amount of undiluted C3F8	marketed	Perfluorocarbon gas (surgical tamponade agent)	Ophthalmology
Probiotics	Probiotics	marketed		Other

Therapeutic area mix

Ophthalmology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Universidade Federal de Pernambuco:

Cite this brief

Drug Landscape (2026). Universidade Federal de Pernambuco — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidade-federal-de-pernambuco. Accessed 2026-05-18.